The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Arena Pharma (I); Mirati Therapeutics
Stock and Other Ownership Interests - Arena Pharma (I); Mirati Therapeutics
Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Abbvie; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Novartis
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Jose M. Pacheco
Honoraria - Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Gerson Lehrman Group; Hengrui Pharmaceutical; Jazz Pharmaceuticals; Novartis; Pfizer; Sanofi; Silverback Therapeutics; Takeda
Research Funding - Pfizer
 
Jared Weiss
Stock and Other Ownership Interests - Achilles Therapeutics (I); Iovance Biotherapeutics; Lyell Immunopharma; Nektar; Nuvalent, Inc.; Vesselon
Consulting or Advisory Role - abbvie; AstraZeneca; Azitra; BeiGene; Blueprint Medicines; Boehringer Ingelheim; EMD Serono; G1 Therapeutics; Genentech; Genmab; Jazz Pharmaceuticals; Jounce Therapeutics; Lilly; Nanobiotix; Pfizer; Regeneron; Saatchi Wellness; SDP Oncology
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; Carefusion (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics; PDS Biotechnology; Sumitomo Dainippon Pharma Oncology
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Shirish M. Gadgeel
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; Daichii-Sanyko; Genentech/Roche; Janssen Oncology; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); Daichii Sanyko (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Elevation Oncology (Inst); Erasca, Inc (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst); I-Mab (Inst); Incyte (Inst); InventisBio (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Nektar (Inst); Numab (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); Ymabs Therapeutics Inc (Inst)
Travel, Accommodations, Expenses - Merck
Other Relationship - AstraZeneca
 
Hirak Der-Torossian
Employment - Mirati Therapeutics
 
Karen Velastegui
No Relationships to Disclose
 
Thian Kheoh
Employment - Mirati Therapeutics; Tocagen
Stock and Other Ownership Interests - Mirati Therapeutics; Tocagen
Travel, Accommodations, Expenses - Mirati Therapeutics; Tocagen
 
James G Christensen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Consulting or Advisory Role - BridgeBio Pharma
Patents, Royalties, Other Intellectual Property - Multiple patents in last 2 years while employed at Mirati Therapeutics covering discovery of KRAS, LSD1, and EZH2 inhibitors. (Inst)
 
Marcelo Vailati Negrao
Consulting or Advisory Role - Merck; Mirati Therapeutics
Research Funding - Alaunos Therapeutics; AstraZeneca; Checkmate Pharmaceuticals; Genentech; Mirati Therapeutics; Novartis; Pfizer; ZIOPHARM Oncology
Other Relationship - Apothecom; Ashfield Healthcare; ZIOPHARM Oncology